ArticleNeurochemical research2026
DNA Topoisomerase IIβ Suppresses Microglial Inflammatory Cytokine Release: A Potential Regulator of Neuroinflammation.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
DNA topoisomerase IIβ (topo IIβ) is a nuclear enzyme that regulates DNA topology and gene expression, especially in post-mitotic cells such as neurons. Although its roles in neural development and transcriptional control are well-established, its involvement in neuroinflammatory processes is still to be investigated. This study aims to investigate whether topo IIβ modulates inflammatory responses in human microglial HMC3 cells under immune-stimulated conditions, considering that microglial cells are pivotal mediators of neuroinflammation in the central nervous system (CNS). Inflammation was induced using lipopolysaccharide (LPS), interferon-gamma (IFNγ), Adenosine triphosphate (ATP), whereas topo IIβ expression was modulated by overexpression and siRNA-mediated silencing. Western blot analysis demonstrated that LPS, IFNγ, and ATP stimulation did not alter the endogenous topo IIβ protein levels, indicating that its protein levels are stable under inflammatory conditions. Analysis of cytokine release indicated that topo IIβ overexpression decreased the release of key proinflammatory cytokines, suggesting an anti-inflammatory role. Conversely, the silencing of topo IIβ resulted in increased cytokine release, suggesting that topo IIβ typically functions to mitigate microglial inflammatory responses. Significantly, treatment with Lipofectamine™ 3000 alone increased cytokine release, indicating an intrinsic immunostimulatory impact of the transfection reagent. Collectively, these findings reveal an unacknowledged function of topo IIβ in attenuating neuroinflammatory signaling in microglia and underscore the necessity for careful interpretation of cytokine data when transfection reagents are present. Topo IIβ may represent a novel therapeutic target for modulating microglial activation in neuroinflammatory diseases.
Indexed as
Identifiers
42776333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.